In a review of seven clinical trials of duloxetine (Cymbalta), researchers found that the drug-treated patients fell into two groups: 76.7% “responded” to the drug, and 23.7% did not. In contrast, “placebo treated patients were characterized by a single response trajectory,” in which they gradually improved. At the end of eight weeks, the drug responders were doing better than the placebo group as a whole, while the drug non-responders were doing worse. When the data from the two drug-treated groups are pooled (responders and non-responders), the outcomes may be no better than for the placebo group.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.